Effects of ipriï¬avone on postmenopausal syndrome and osteoporosis.
Gynecol Endocrinol
; 26(2): 76-80, 2010 Feb.
Article
em En
| MEDLINE
| ID: mdl-19672742
ABSTRACT
OBJECTIVE:
To investigate the therapeutic effects of ipriflavone on postmenopausal syndrome and osteoporosis in women.METHODS:
A randomized and double-blind study was conducted. Sixty postmenopausal women with osteoporosis were chosen and they were randomly divided into three groups Treatment group I was given oral compound calcium acid chelate and Vitamin AD guttate; treatment group II was given oral compound calcium acid chelate, Vitamin AD guttate and ipriflavone; Control group was given placebo and compound calcium acid chelate. The postmenopausal syndrome, bone mineral density (BMD), and bone biochemical markers were assessed 6 and 12 months after the treatment.RESULTS:
In treatment group II, hot flush and ostalgia syndromes were dramatically relieved, BMD and serum calcium level increased markedly and alkaline phosphatase, parathyroid hormone and tartrate-resistant acid phosphatase decreased markedly, comparing with treatment group I and control group (p < 0.05).CONCLUSION:
Ipriflavone could inhibit bone resorption and promote bone formation. It is an effective drug for the prevention and treatment to menopausal syndrome and osteoporosis. Ipriflavone could be used as a supplement to estrogen replacement treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Osteoporose Pós-Menopausa
/
Fitoestrógenos
/
Isoflavonas
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article